DIR Fee Relief Urged in NACDS’ New Cable, Broadcast, Digital Ads NACDS: “Dire” problem for patients, pharmacies must be fixed in drug-pricing bill
NACDS: “Dire” problem for patients, pharmacies must be fixed in drug-pricing bill
NACDS: “Dire” problem for patients, pharmacies must be fixed in drug-pricing bill
Pharmacy groups unite to laud bipartisan Congressional focus on closing the loophole that inflates drug costs for patients and Medicare, and jeopardizes pharmacies.
Bipartisan support is strong for a legislative fix to the loophole that inflates drug costs for patients and for Medicare, and that jeopardizes pharmacies.
DIR fee relief is motivating a record-breaking NACDS RxIMPACT Congressional letter-writing campaign. The effort to end the abuse of DIR fees includes three focuses right now. Learn more.
Grassroots engagement supporting Phair Pricing Act is crucial for pharmacy viability and to reduce seniors' out-of-pocket drug costs.
NCPA and NACDS: "We are disappointed and frustrated that this final rule fails to finalize pharmacy DIR reform as proposed, to the detriment of seniors and community pharmacies. Our organizations have been joined by many pharmacists, pharmacy stakeholder groups, patient advocacy organizations, patients, and members of Congress in advocating that all pharmacy price concessions be included at the point of sale – or eliminated altogether – to provide senior patients with lower costs and pharmacies with more certainty..."
Medium post urges action on DIR fee relief in final Medicare rule.
A poll of registered voters, conducted by Morning Consult and commissioned by NACDS, includes findings that can help make the case for direct and indirect remuneration (DIR) fee relief, and for broader reimbursement issues.
NACDS’ Congressional statement keys on lowering patients’ costs at pharmacy counter, reducing overall healthcare costs, and fostering pharmacy viability by preventing below-cost reimbursement.
Morning Consult today published an opinion piece by the NACDS entitled “DIR Fee Reform: Lining Up Another Win for Patients on Drug Costs.”